摘要
目的观察脂微球前列腺素E1对早期糖尿病肾病患者血清可溶性细胞间黏附分子-1(sICAM-1)及超敏C反应蛋白(hs-CRP)水平的影响,进一步探讨其治疗糖尿病肾病的机制。方法选取早期糖尿病肾病患者64例,随机分为治疗组(n=32)及对照组(n=32),对照组常规饮食控制、口服降糖药或胰岛素治疗,治疗组在此基础上加用脂微球前列腺素E1注射液进行治疗,脂微球前列腺素E110μg入壶(生理盐水)静脉点滴1,次/d,连续治疗14d,测定两组患者的sICAM-1和hs-CRP水平。结果治疗组血清sICAM-1和hs-CRP水平较治疗前显著降低,且差异有统计学意义(P<0.01)。结论早期DN患者接受脂微球前列腺素E1治疗后sICAM-1和hs-CRP表达降低,提示脂微球前列腺素E1扩张血管的同时,亦可能降低sICAM-1、hs-CRP的表达,改善炎症状态而保护肾脏。
Objective： To investigate the effect of lipo-prostaglandin E1 on serum soluble intercellular adhesion molecule-1（sICAM-1） and high sensitive-C reactive protein（hs-CRP） levels in patients with early diabetic nephropathy（DN）.Methods： A total of 64 patients with early DN were randomly divided into treatment group（n=32） and control group（n=32）,which were both treated with dietary control and oral hypoglycemic drugs or insulin,meanwhile,the treatment group were treated with lipo-prostaglandin E1 10 μg·d-1 into the pot of static drops for 14 days.The levels of sICAM-1 and hs-CRP in each group were detected.Results： The levels of sICAM-1 and hs-CRP were decreased significantly in lipo-prostaglandin E1 treatment group after 14 days（P0.01）.Conclusion： lipo-prostaglandin E1 may depress the expression of sICAM-1 and hs-CRP,which may be one of the mechanisms for delaying the progress of early DN.
出处
《泰山医学院学报》
CAS
2011年第8期576-578,共3页
Journal of Taishan Medical College
